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Two-Plasmid Packaging System for Recombinant
Adeno-Associated Virus
Qiushi Tang,1,2 Allison M. Keeler,1,2 Songbo Zhang,1,2 Qin Su,2,3 Zhuoyao Lyu,1,2
Yangfan Cheng,1,2 Guangping Gao,2–4 and Terence R. Flotte1,2,4,*
Abstract
A number of packaging systems are available for production of recombinant adeno-associated virus vectors
(rAAVs). Among these, the use of a two-plasmid cotransfection system, in which Rep and Cap genes and
Ad helper genes are on the same plasmid, has not been frequently employed for good manufacturing prac-
tices (GMP) production, even though it presents some practical advantages over the common three-plasmid
(triple) transfection method. To confirm and expand the utility of the two-plasmid system, we generated GMP-
compatible versions of this system and used those package reporter genes in multiple capsid variants in direct
comparison with triple transfection. Vector yields, purity, and empty-to-full ratios were comparable between
double and triple transfection methods for all capsid variants tested. We performed an in vivo side-by-side
comparison of double and triple transfection vectors following both intravenous injection and intramuscular
injection in mice. Expression and transduction were evaluated in muscle and liver 4 weeks after injection. Addi-
tional studies of bioactivity were conducted in vivo using packaged vectors carrying a variety of cargos, includ-
ing the therapeutic transgene, microRNA, and single- or double-stranded vector. Results showed that cargos
packaged using double transfection were equivalently bioactive to those packaged using a triple transfection
system. In conclusion, these data suggest the utility of midrange (1E12-1E16) GMP-compatible packaging of
adeno-associated virus (AAV) vectors for several AAV capsids.
Keywords: AAV; viral vectors; plasmids; gene expression; gene therapy; gene transfer
Introduction
The production of recombinant adeno-associated virus
(AAV) vectors in the relative absence of wild-type
AAV was first accomplished by Samulski, Chang, and
Shenk using cotransfection of adenovirus 5-infected
HeLa cells with an AAV2 inverted terminal repeat
(ITR)-flanked vector cassette and AAV2 ITR-deleted
construct to provide rep and cap functions in trans.1
Initially, it was assumed that supplying greater levels
of expression of both the Rep78/68 and Rep52/40
proteins would increase packaging. However, it was
subsequently shown that highly regulated rep gene ex-
pression (particularly moderating the expression of
Rep78/68) would increase the yield of rAAVs pack-
aged under such conditions.2 A further substantial im-
provement in the efficiency of the upstream process
was achieved by substituting transfection of three of
the adenoviral helper genes (E2a, E4, and VA RNA)
into cells that constitutively express adenoviral E1a
and E1b genes, most commonly HEK-293 cells.3
This process of triple transfection of the ITR-flanked
vector plasmid, Rep/cap plasmid, and adenoviral
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gene helper plasmid has become an established and
highly flexible manufacturing method. Grimm et al.
further improved this approach by combining the
Rep/cap and adenovirus helper gene capsids into a
single helper, pDG.4,5 However, this two-plasmid
system has not been used as frequently for clinical
manufacturing as the common triple transfection sys-
tem or the baculovirus system.6–13
The recent emergence of numerous instances of clin-
ical efficacy being proven in rAAV-mediated gene ther-
apy trials for single-gene disorders has precipitated a
greatly increased demand for current good manufactur-
ing practices (cGMP) reagents that will enable this plat-
form to be disseminated more broadly to the estimated
10,000 distinct monogenic disorders of humans.14–24
We sought to develop a cost-sensitive, streamlined
good manufacturing practices (GMP)-compatible set
of reagents that would enable rapid cross-translation
of rAAV platform technologies from one monogenic
disease to other monogenic diseases affecting the
same organ or cell type.25 These constructs were de-
rived using a strategy similar to that of Grimm et al.,4
with minor backbone modifications to improve GMP
compatibility and allow the insertion of multiple, dif-
ferent, serotype capsid genes that would be of interest
in clinical trials. In such an approach, clinical success
with a particular rAAV capsid variant, route, and
dose combination in one genetic disease affecting one
cell type would provide a strong rationale for its use
in the treatment of other genetic diseases affecting
the same cell type, so long as the same capsid/route/
dose combination was used.
Obstacles to this approach might include the avail-
ability of reagents needed to manufacture rAAVs in a
relatively versatile and low-cost manner. To address
these obstacles, we tested a set of GMP-compatible
rAAV packaging plasmids that combine a number of
the features of previously reported technology. In this
study, we report that the use of a two-plasmid system
instead of a three-plasmid system simplifies the trans-
fection step and decreases by one-third the cost of
manufacturing the GMP-compatible plasmid, thus
resulting in significant cost savings in the cGMP pack-
aging of rAAVs.26
Results
To create a two-plasmid system for AAV packaging,
the Ad5 helper genes were cloned into a plasmid con-
taining ITR-less AAV Rep and Cap genes, creating
the pQT-packaged plasmid that contains both AAV
Rep and Cap and the Ad helper function (Fig. 1).
Importantly, kanamycin resistance was used for bacte-
rial selection to make the pQT plasmid appropriate for
clinical use. To package rAAVs using this system, the
pQT plasmid is transfected with the transgene plasmid
flanked by AAV ITRs (Fig. 1A). To create multiple
AAV capsid variants from this two-plasmid system,
separate pQT helper plasmids must be created for
each capsid and are therefore referred throughout the
article with the nomenclature of pQT-8 representing
the two-plasmid helper system for packaging the
AAV capsid variant AAV8 (Fig. 1B).
To determine the optimal ratio of the two plasmids
for transfection, four different molar ratios (1:1, 1:0.5,
1:0.25, and 1:0.125, transgene:helper) of pQT-8 were
transfected into HEK cells and viruses were purified
as previously described. Silver staining of vector parti-
cles indicates that ratios of 1:1 and 1:0.05 (transgene
plasmid: pQT-8 plasmid) produce the greatest number
of viral particles as well as minimal contaminating
bands (Fig. 2). Digital droplet polymerase chain reac-
tion (PCR) was used to determine genome copies per
prep and confirmed that ratios of 1:1 and 1:05 produced
the best yield. The results are summarized in Table 1,
indicating the vector particle and genome copy per
mL and total yield per prep at different molar ratios.
There are instances where the two titer methods differ
slightly in their values in either direction (physical vs.
genome copy), but these differences appear to be within
the error of the measurement technique.
Next, to compare the pQT system with the well-
established triple transfection system, different AAV
capsid variants were packaged side by side using either
the pQT helper or triple transfection helper plasmids.
pQT plasmids were packaged at a molar ratio of 1:1
and triple transfection packaging used a 1:1:1 weight
ratio of plasmid, in which the weight of the transgene
plasmid was matched between the pQT method and
triple transfection system.
To assess the applicability of the pQT method across
different plasmid variants, AAV1, AAV5, AAV8, and
AAV9 capsids were tested comparing the two packag-
ing systems. Viral particle production was analyzed
by silver staining for the different capsid variants
packaged by either pQT or triple transfection (Fig. 3).
Results showed that expression levels of viral capsids
using pQT or triple transfection were similar, although
some of the triple transfection AAVs were more con-
centrated than the pQT-packaged AAVs, resulting in
higher viral particles (VP)/mL. This difference did not,
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FIG. 1. pQT plasmid packaging system. Red—adenoviral (Ad) genes, purple—AAV genes. (A) Schematic
comparing the standard triple-plasmid transfection system (right) with the double-plasmid transfection
using the pQT helper plasmid. ITRs designated in yellow, and transgene of interest in green. (B) Plasmid
map of the pQT plasmid. Bacterial genes designated in green. AAV, adeno-associated virus; ITRs, inverted
terminal repeats.
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however, correlate with a higher total yield (Table 2).
Visualization of AAV capsids by transmission electron
microscopy after purification demonstrated that the
capsid structure and ratio of empty to full capsids
were comparable across the two transfection systems
and different capsids (Supplementary Fig. S1). Genome
copies were again compared, and total yield was calcu-
lated and is reported in Table 2. Across all capsid var-
iants, pQT and triple transfection titers were similar
and within normal deviations of viral production.
Next, we wanted to test how the pQT-packaged viruses
behaved in vivo. C57bl6 mice were injected with either
pQT-produced or triple transfection-produced AAVs
through the tail vein for AAV5, AAV8, and AAV9
(1 · 1012 vg) or through intramuscular injection for
AAV1 (1 · 1011 vg). Three weeks postinjection, animals
were sacrificed, and tissues were collected for quantifica-
tion of vector genomes and immunohistochemistry.
Measurements for AAV1 vector genomes in liver and
muscle showed no significant differences between the
two methods (Fig. 4A). For AAV5, 8, and 9, tissues
were collected from the liver and again no significant dif-
ferences were observed in the vector genomes between
the two methods of viral production (Fig. 4B–D). Expres-
sion of GFP within the tissue was visualized by immuno-
histochemistry staining within the muscle (Fig. 5A) or
liver (Fig. 5B). Widespread expression was observed
within the muscle after treatment using AAV1 vectors
packed by both systems (Fig. 5A). Although different ex-
pression patterns were observed in the liver among capsid
variants (with mostly perivascular cuffing observed for
AAV5), the expression did not vary as a function of
the transfection method (Fig. 5B) and no detectable dif-
ferences were observed between transduction and expres-
sion of AAV capsids in vivo.
Finally, to test the in vivo functionality of transgenes
packaged by the pQT system, AAV8 vectors were
packaged by pQT or the triple transfection system to
produce the human alpha-1 antitrypsin (AAT) trans-
gene. Rag/ mice were injected intravenously with
vectors packaged either by the pQT or triple transfec-
tion method and bled biweekly to measure AAT levels
in the serum. No significant differences were observed
in serum AAT levels of vectors packaged by the two
methods and injected intravenously (Fig. 6A).
To further show that the pQT vector system could
efficiently package transgenes, even those with complex
structures such as microRNAs, vectors were packaged
using both methods with a transgene that contained
AAT with a c-myc tag along with a microRNA target-
ing the Z mutation of human AAT. Vectors prepared
using the two methods were then administered to PiZ
transgenic animals, which allowed us to test for both
transgene-mediated augmentation of AAT by c-myc
using the enzyme-linked immunosorbent assay (ELISA)
and microRNA-mediated knockdown of PiZ. Results
showed that treatment with pQT-generated vectors led
to both increased ATT expression (Fig. 6B) and knock-
down of PiZ (Fig. 6C), with no significant difference
being found between the two packaging methods. No dif-
ferences were observed in biological activity of the virus
regardless of the production method.
Discussion
In this study, we demonstrate that a two-vector system
can be used to produce AAV that behaves similarly to
triple transfection-produced virus, both in its ease of
FIG. 2. Silver-stained protein gels of viral
capsid proteins from vector preparations with
two-capsid systems. Silver stain of SDS-PAGE gel
of purified pQT8 virus packed at different ratios
of the transgene plasmid: pQT packaging
plasmid. SDS-PAGE, sodium dodecyl sulfate–
polyacrylamide gel electrophoresis.
Table 1. Optimization of Different Molar Ratios
for pQT Packaging
Ratio 1:1 1: 0.5 1: 0.25 1: 0.125
VP/mL 5.0 · 1011 1.0 · 1012 1.0 · 1012 1.0 · 1011
GC/mL 1.6 · 1012 1.9 · 1012 7.2 · 1011 9.7 · 1010
Volume, mL 2.4 2.4 2.4 2.0
Total yield (GC) 3.8 · 1012 4.6 · 1012 1.7 · 1012 1.9 · 1011
Ratio of transgene plasmid: pQT packaging plasmid.
Genome copies (GC) were detected by digital droplet PCR and viral
particles (VP) were detected by silver stain.
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production and its biological activity in vivo. Dirk
Grimm first published the use of a two-vector system,
pDG, combining packaging and helper functions,4,5
which when scaled for clinical production, allows for
significant cost savings in production of two plasmids
versus three plasmids. We have further optimized
this system for GMP-compatible, medium-scale clini-
cal production by introducing kanamycin as the bacte-
rial antibiotic resistance gene on the pQT plasmid.
The Grimm Laboratory pDG constructs demon-
strated the feasibility of a two-plasmid approach
some two decades ago, and yet this approach has still
not become the predominant approach to transient
transfection-based rAAV manufacturing. It is not
clear why this is the case, but the current report
shows how this approach can be built upon to yield a
lower cost method that allows for great flexibility in
the choice of AAV capsid serotype in production of
AAV vectors. This improvement should hasten the
speed toward clinical development of any number of
rAAV constructs. Our experience with contract
manufacturing organizations indicates a standard cost
based on the number of plasmids. While these cost sav-
ings could potentially be offset if yields of plasmids
with the pQT series were lower than with alternative
plasmids, this has not been our experience (Supple-
mentary Table S1).
It has been the aspiration of many rare disease
researchers to reduce rAAV gene therapy for autoso-
mal recessive disorders to a single GMP compatible
FIG. 3. Silver-stained protein gel of viral capsid proteins from multiple capsid variants. After purification of
AAV particles by either the traditional triple transfection system or pQT packaging, 5 lL of virus was run on
SDS-PAGE gel and stained with silver stain. VP1, VP2, and VP3 capsid proteins are designated on the gel.
Quantification of gel staining was preformed and recorded as viral particles per mL in Table 1.
Table 2. Viral Titer Comparison
Capsid variants
AAV1 AAV5 AAV8 AAV9
Transfection Triple pQT Triple pQT Triple pQT Triple pQT
VP/mL 2.4 · 1013 1.3 · 1013 1.8 · 1013 2.3 · 1013 1.0 · 1013 8.0 · 1012 9.0 · 1012 5.5 · 1012
GC/mL 4.2 · 1012 5.2 · 1012 6.7 · 1012 7.6 · 1012 4.6 · 1012 3.0 · 1012 6.5 · 1012 2.5 · 1012
Total volume (mL) 2.9 1.9 3.0 3.2 2.0 3.0 2.0 3.0
Total yield (GC) 1.2 · 1013 9.9 · 1012 2.0 · 1013 2.4 · 1013 9.2 · 1012 9x 1012 1.3 · 1013 7.5 · 1012
Genome copies (GC) were detected by digital droplet PCR and viral particles (VP) were detected by silver stain.
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FIG. 4. Vector genome quantification after in vivo delivery of different capsid variants. (A) 1E10 vg were
intramuscularly injected into four animals per group. Tissue was collected from the muscle injection site
and liver and vector genomes were analyzed by qPCR targeting polyA tail. (B–D) 1E11 vg were
intravenously injected into four animals per group. Liver tissue was collected and vector genomes were
analyzed by qPCR targeting polyA tail. qPCR, quantitative polymerase chain reaction.
FIG. 5. Immunohistochemical detection of GFP expression in the liver and muscle after in vivo AAV
administration of multiple capsid variants. DAB staining of GFP expression (brown) within the liver (A) and
muscle (B) after AAV administration through intramuscular injection (AAV1) or intravenous injection (AAV5,






































































































































































































































































































































































































































































platform regardless of serotype, dosage, and route of
administration.25 For this concept to truly become a re-
ality, it will require a generic manufacturing platform
such as the one described here. We currently have
generated the following pQT plasmids to represent a
number of clinically relevant capsid variants: AAV1
(pQT-1), AAV3b (pQT-3b), AAV5 (pQT-5), AAV7
(pQT-7), AAV8 (pQT-8), AAV9 (pQT-9), AAV-
RH8 (pQT-RH8), AAV-RH10 (pQT-RH10), and
AAV-PHP.B (pQT-PHP.B).
The work to optimize plasmid transfection-based
manufacturing of rAAVs, while hampered by limita-
tions of transient transfection, nonetheless provides
us with an important platform for disseminating this
mode of therapy to many individuals suffering from
single-gene disorders.
There is no question that the availability of a readily
translatable platform for rAAV gene therapy is impor-
tant to the future of gene therapy. The University of
Massachusetts Medical School (UMMS) platform is
readily available for licensure to any academic medical
center with potential interest in pursuing rAAV gene
therapy. The plasmids created here could help in crea-




The pQT vector is designed by cloning AAV Rep and
Cap genes from the AAV packaging plasmid and Ad
helper genes onto a backbone plasmid containing the
kanamycin-resistant gene. The sequences chosen were
similar to those described by Grimm et al.4 The plas-
mids were constructed using GenScript cloning. The
entire fragment from AvrII to SalI was used to substi-
tute the kanamycin resistance gene in the place of the
ampicillin resistance gene. In addition, a ClaI site was
engineered 3¢ to the AAV cap sequence to enable the
introduction of various new capsid sequences, includ-
ing those for AAV1, AAV3B, AAV5, AAV8, AAV9,
AAVrh8, AAVrh10, and PHP.B. See Figure 1 for sche-
matic representation. These constructs included se-
quences of the adenovirus ITRs, but these were not
tested specifically for rescue as this was not a primary
research question for these studies.
Virus production
The constructs were packaged into AAVs by transient
HEK 293 cell (triple or double) transfection and puri-
fied by CsCl sedimentation as previously described by
the viral vector core at the University of Massachu-
setts Medical School,27 a method based on transfec-
tion of HEK293 cells grown in roller bottles, with
1 · 108 cells per bottle and 10 bottles per prep. Triple
transfection was performed at a 1:1:1 weight ratio with
1.5 mg each of the transgene plasmid, packaging plas-
mid, and adeno helper plasmid (unless otherwise
specified). pQT packaging was performed at different
molar ratios (as stated in text) with 1.5 mg of the
transgene plasmid matched to the triple transfection
system.
Titration of vector preparations
The vectors were titered for genome titer by droplet
digital PCR (QX200 ddPCR system; Bio-Rad) using
the EGFP or SV40 prime and probe. Probes were
used with the Bio-Rad protocol for droplet digital
PCR and TaqMan assay master mix. All amplifications
were performed in 20-lL reaction volumes run for 40
cycles. The following primer–probe combinations
were used: eGFP-F: AGCAAAGACCCCAACGAGAA,




and SV probe: 6FAM-AGCATTTTTTTCACTGCATT
CTAGTTGTGGTTTGTC-TAMRA. AAV testing sam-
ples and a reference standard AAV of known titer
were treated with DNase I first to eliminate residual
vector plasmid DNA and then with proteinase K to de-
stroy DNase I and release DNase I-resistant packaged
vector genomes, followed by heat inactivation of pro-
teinase K. Serially diluted AAV samples and the refer-
ence standard were each subjected to droplet PCR in a
20-lL reaction volume. The PCR conditions are 10 min
at 95C, followed by 40 cycles of 30 sec at 94C and
1 min at 60C, ending with 10 min at 98C. Semiquan-
titative capsid titer and purity (vector particles) were
assessed by 4–12% sodium dodecyl sulfate (SDS)–
acrylamide gel electrophoresis and silver staining
(Invitrogen). A precalibrated AAV vector with a
known vector genome titer and a > 95% full-to-empty
ratio was used as a reference standard, serially diluted,
and loaded side by side with testing articles of AAV sam-
ples onto SDS-polyacrylamide gel electrophoresis (SDS-
PAGE) for analysis. After silver staining of the gel, purity
of each AAV testing article was visually examined for
the presence of AAV VP1, VP2, and VP3 protein
bands only at a ratio of 1:1:10, respectively, but absence
of other protein bands. The capsid titer of each AAV
Tang, et al.; BioResearch Open Access 2020, 9.1
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testing article was semiquantitatively determined on a
gel scanner. Briefly, the band size and intensity of VP3
protein of the serially diluted reference standard AAV
were measured to establish a standard curve, then the
VP3 band size and intensity of each testing article
were measured and its capsid titer semiquantitatively
assessed by using the reference standard curve.
Animals
All experimental procedures were approved by the
Institutional Animal Care and Use committee at the
University of Massachusetts Medical School. Rag mice
were obtained from Jackson Laboratory B6.129S7-
Rag1<TM1MOM>/J. The PiZ transgenic mice were
used in this study, as has been previously described.28
Intramuscular injections were administered into the
right hindlimb at 50-lL volume, as previously de-
scribed.29 Intravenous injections were administered
into the tail vein at a volume of 200 lL per mouse.
Vector genomes
Vector genomes were determined as previously de-
scribed.30 DNA was extracted from the liver and mus-
cle using the DNeasy Blood and Tissue Kit (Qiagen).
The following RGB poly A primer/probe was used:
probe 56-FAM/ATGAAGCCCCTTGAGCATCTGAC
TTCT/36-TAMSp, F: ATTCCAACACACTATTGC
AATG, R: GCCAAAAATTATGGGGACAT. The stan-
dard curve for quantitative polymerase chain reaction
was generated from the same pCB-EGPFP that was
packaged and normalized to genome copies per 100 ng
genomic DNA.
GFP immunohistochemistry
GFP immunohistochemistry was carried out by the
Molecular Pathology Core at University of Florida.
Briefly, 4-mm serial sections were deparaffinized and
treated with citra (BioGenex, Fremont, CA) at 98C for
30 min. Background Sniper (Biocare Medical, Walnut
Creek, CA) was used to reduce unspecific background
staining. Sections were incubated with rabbit anti-GFP
(1:2000; Abcam, Cambridge, MA) for 60 min. The stain
was visualized using MACH 2 Gt · rabbit HRP polymer
(Biocare Medical), DAB chromogen (Biocare Medical),
and CAT hematoxylin counterstain (Biocare Medical).
Enzyme-linked immunosorbent assays
For all ELISAs (human AAT, human PiZ, and c-myc),
high binding 96-well plates (Immulon4; Dynatech
Laboratories) were coated with the relevant capture an-
tibody in 100 lL of Voller’s buffer overnight at 4C. All
subsequent incubations were done at room temperature
for 1 h and plates were washed with phosphate buffered
saline containing 0.05% Tween 20. Detection antibody
was used at 1:5000 goat anti-hAAT-horseradish perox-
idase (HRP, Cat#A80-122P; Bethyl Laboratories, Inc.).
Human AAT ELISA: As previously described,31
blocking was done with 1% milk; 1:000 capture anti-
body goat anti-human AAT (Cat#A80-122A; Bethyl
Laboratories, Inc.) was used. Human plasma-purified
AAT was used to create the standard curve (Cat#16-
16-011609; Athens Research and Technology).
Human PiZ-AAT ELISA: Blocking was done with
3% bovine serum albumin (BSA); 1:000 dilution cus-
tom capture antibody was produced in our laboratory
(UMMS-PiZ-mAb). In-house standard was used to
create the standard curve.
c-myc ELISA: Blocking was done with 3% BSA;
1:1000 c-myc capture antibody (Cat#GTX30518; Gen-
eTex, Inc.) was used. In-house standard was used to
create the standard curve.
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Abbreviations Used
AAT ¼ alpha-1 antitrypsin
AAV ¼ adeno-associated virus
BSA ¼ bovine serum albumin
cGMP ¼ current good manufacturing practices
GC ¼ genome copies
GMP ¼ good manufacturing practices
HRP ¼ horseradish peroxidase
ITRs ¼ inverted terminal repeats
qPCR ¼ quantitative polymerase chain reaction
rAAV ¼ recombinant adeno-associated virus vector
SDS ¼ sodium dodecyl sulfate
SDS-PAGE ¼ sodium dodecyl sulfate–polyacrylamide gel
electrophoresis
UMMS ¼ University of Massachusetts Medical School
VP ¼ viral particles
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